Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28228645 | 0.82 | ALDH1A1 (0.42) | CYP3A4TSHRALDH1A1MAPK1TP53 | |
| SCHEMBL28243411 | 0.81 | TSHR (0.46) | CYP3A4TSHRALDH1A1MAPK1TP53 | |
| SCHEMBL395142 | 0.80 | ALDH1A1 (0.47) | CYP3A4TSHRALDH1A1MAPK1TP53 | |
| SCHEMBL19972039 | 0.79 | CYP3A4 (0.43) | CYP3A4TSHRALDH1A1MAPK1TP53 | |
| Hydrochloric Acid SCHEMBL29008323 | 0.77 | ALDH1A1 (0.45) | CYP3A4TSHRALDH1A1MAPK1TP53 | |
| Bromide SCHEMBL28821509 | 0.77 | ALDH1A1 (0.45) | CYP3A4TSHRALDH1A1MAPK1TP53 | |
| Water SCHEMBL27673190 | 0.77 | ALDH1A1 (0.45) | CYP3A4TSHRALDH1A1MAPK1TP53 | |
| SCHEMBL24522014 | 0.75 | CYP3A4 (0.30) | CYP3A4TSHRMAPK1 | |
| SCHEMBL2131880 | 0.75 | ALDH1A1 (0.50) | CYP3A4TSHRALDH1A1MAPK1TP53 | |
| SCHEMBL1610039 | 0.75 | CYP3A4 (0.30) | CYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957241-B2 | Aromatic diamine, an intermediate therefor, a method for producing the aromatic diamine, and a method for producing the intermediate therefor | SEIKA CORPORATION (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20180079732-A1 | AROMATIC DIAMINE, AN INTERMEDIATE THEREFOR, A METHOD FOR PRODUCING THE AROMATIC DIAMINE, AND A METHOD FOR PRODUCING THE INTERMEDIATE THEREFOR | SEIKA CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
| CN-107531652-A | Aromatic diamine, intermediate thereof, and processes for producing these | 精化株式会社 | 2018-01-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079732-A1 | AROMATIC DIAMINE, AN INTERMEDIATE THEREFOR, A METHOD FOR PRODUCING THE AROMATIC DIAMINE, AND A METHOD FOR PRODUCING THE INTERMEDIATE THEREFOR | WEE1, WEE2, WASF2 | CYP3A4 933/4885TSHR 4030/4885ALDH1A1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.